Fintel reports that on September 12, 2024, Craig-Hallum upgraded their outlook for Champions Oncology (NasdaqCM:CSBR) from Hold to Buy. Analyst Price Forecast Suggests 52.62% Upside As of August 26, ...

Champions Oncology, Inc. (Nasdaq:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration ...

The 2025 Safety Champion Awards will open in January 2025. Follow Verkada on LinkedIn for more news and announcements.

Prime Video is using low-latency technology across "the majority of devices", delivering live action from grass to glass in ...

The company reported quarterly earnings of 11 cents per share which beat the analyst consensus estimate of a loss of $0.3 per ...

The International Cricket Council (ICC) delegation, currently visiting Pakistan, has expressed satisfaction with the ...

Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft ...

The firm increased its portfolio allocation in CSBR by 1,586.70% over the last ... center of excellence to develop transformative technology and accelerate oncology research and development.